LifeSci Capital analyst Kate Dellorusso has maintained their bullish stance on SLNO stock, giving a Buy rating on September 17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kate Dellorusso has given her Buy rating due to a combination of factors, primarily focusing on the positive reception of Soleno Therapeutics’ Vykat XR in the real-world setting. The drug, which is the first approved therapy for hyperphagia in Prader-Willi Syndrome (PWS), has been well-received by clinicians despite not being curative. Experts, including those without prior experience with Vykat XR, are familiar with its safety profile due to its parent molecule, diazoxide, used in congenital hyperinsulinism. This familiarity has led to careful pre-treatment screening and cautious dose escalation to manage potential risks.
Furthermore, the steady increase in FAERS entries is attributed to the broad uptake of the drug rather than emerging safety issues, suggesting a positive risk-benefit ratio for properly selected patients. The unmet need in PWS and the severity of the condition support the continued use of Vykat XR, with experts estimating that a significant portion of patients will remain on the therapy long-term. Despite competition from other companies, the market is expected to accommodate multiple therapies, and the disciplined patient selection is anticipated to drive the broader adoption of Vykat XR.
In another report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $110.00 price target.